Log In
Print
BCIQ
Print
Print this Print this
 

dolutegravir/abacavir/lamivudine (572-Trii) (S-349572/S-265744/S-247303)

  Manage Alerts
Collapse Summary General Information
Company ViiV Healthcare Ltd.
DescriptionSingle tablet formulation of integrase inhibitor and NRTI
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor; HIV reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection; Treat HIV/AIDS
Regulatory Designation

U.S. - Undisclosed Review (Treat HIV-1 infection);
EU - Standard Review (Treat HIV-1 infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today